Desmopressin (DDAVP) - Synthetic Vasopressin Analog — Pituitary & Renal
FDA-approved synthetic vasopressin analog for central diabetes insipidus, nocturnal enuresis, and hemostatic disorders.
Overview
Desmopressin (1-desamino-8-D-arginine vasopressin, DDAVP) is a synthetic analog of vasopressin (ADH) with enhanced antidiuretic potency and minimal vasopressor effects. FDA-approved for central diabetes insipidus, nocturnal enuresis in children ≥6 years, and hemophilia A/von Willebrand disease. It acts on V2 receptors in renal collecting ducts to increase water reabsorption and reduce urine output. Cochrane review (41 RCTs, n=2,760) showed 1.34 fewer wet nights/week in nocturnal enuresis. Long-term studies confirm safe, effective antidiuresis in central DI with proper dosing and fluid restriction.
Indications
- Central diabetes insipidus (NOT nephrogenic DI)
- Nocturnal enuresis in children ≥6 years
- Hemophilia A (mild, with Factor VIII >5%)
- von Willebrand disease (Type 1)
- Nocturia (off-label in adults)
Mechanism of Action
Central DI: pituitary fails to secrete ADH. Enuresis: nocturnal polyuria exceeds bladder capacity
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Desmopressin acetate 0.1-0.2 mg tablets | 0.1-1.2 mg/day total | Divided into 2-3 doses | Individualize based on antidiuretic response; oral dose ~20x higher than intranasal |
| Desmopressin 0.2 mg tablet | 0.2 mg at bedtime (initial) | Once nightly | May titrate up to 0.6 mg; ages ≥6 years; limit fluids 1h before dose until morning |
| Desmopressin nasal spray | 20 mcg (1 spray) at bedtime | Once nightly | Equivalent to 200 mcg oral; 20 mcg intranasal ≈ 0.2 mg oral |
| Desmopressin injection | 0.3 mcg/kg IV or SC | Single dose 30 min before minor surgery or bleeding episode | Increases Factor VIII and vWF levels; NOT for severe hemophilia |
Evidence Grade
GRADE A
Safety & Contraindications
- ⚠️ PRESCRIPTION MEDICATION - Physician supervision required
- HYPONATREMIA/WATER INTOXICATION RISK: Strict fluid restriction required (limit fluids 1h before dose until 8h after)
- Maximum single fluid intake: 240 mL (8 oz) during treatment
- Contraindicated: Age <6 years (enuresis), <3 years (DI), renal impairment, hyponatremia, polydipsia
- Drug interactions: Tricyclic antidepressants, SSRIs, chlorpromazine, opiates, NSAIDs, lamotrigine (↑ hyponatremia risk)
- Monitor serum sodium if on chronic therapy or with intercurrent illness
- NOT for nephrogenic diabetes insipidus (will not work)
- Discontinue if headache, nausea, vomiting, weight gain (signs of water retention)